Blog

eCTD is the digital standard for drug regulatory submissions. Learn the five modules, key application types, and how AuroraPrime keeps content consistent.

Before a pharmaceutical sponsor can test an investigational drug in humans or sell it commercially, it must submit a comprehensive package of clinical, nonclinical, and quality evidence to the relevant health authority. eCTD is the internationally recognized format that defines how to organize and deliver that package.

The dossier spans five modules, from regional administrative data through full clinical trial evidence, with content generated across years of drug development. How consistently that content is authored, cross-referenced, and maintained across all five modules often determines whether a submission withstands regulatory scrutiny or generates queries before review begins.

What Does eCTD Mean?

eCTD stands for Electronic Common Technical Document, the electronic equivalent of the paper-based CTD. It is the standardized interface between pharmaceutical companies and global health authorities for drug and biologic registration submissions.

Developed under the International Council for Harmonisation (ICH), the eCTD specification governs how submission content must be organized, delivered, and managed throughout a product's regulatory lifecycle. ICH M8 is the governing guideline, defining both the technical architecture and the operational requirements for compliant submissions.

The "electronic" element goes further than file format:

• eCTD submissions use an XML backbone to structure content files, metadata, and lifecycle instructions into a single, machine-readable package. 

• Regulators can navigate the dossier systematically, track changes between submission sequences, and identify exactly what is new or replaced without relying on cover letters to explain version differences. 

• The XML index enforces document granularity: each study report, each summary section, and each regional administrative file is a distinct, individually tracked component.

eCTD is now accepted or required by more than 60 regulatory authorities globally, including the US Food and Drug Administration (FDA), EMA, Japan Pharmaceuticals and Medical Devices Agency (PMDA), Health Canada, South Korea Ministry of Food and Drug Safety (MFDS), and agencies across the Gulf Cooperation Council.

The current primary specification, eCTD v3.2.2, remains the standard for most active submissions. eCTD 4.0 is being adopted across major regulatory markets on staggered timelines.

What is the Difference Between CTD and eCTD?

The Common Technical Document (CTD) is the paper-based predecessor, a physically organized regulatory dossier standardized by the applicable ICH guideline. It established what information a drug application must contain and how that information must be structured across five modules.

The eCTD is the electronic successor, designed on the same five-module content structure and subject to the same regulatory content requirements.

The difference between the two is in how that content is packaged, transmitted, and managed over time.

Dimension	CTD	eCTD
Format	Paper binders or flat PDF files with no standardized electronic structure	XML-backed digital package with structured file naming, folder organization, and a machine-readable index
Delivery	Physical submission or basic electronic transfer without a standardized gateway	Secure digital delivery through a regulatory electronic submissions gateway
Version Control	No inherent mechanism; version changes described manually in cover letters	Explicit lifecycle attributes (new, replace, delete) attached to each document in the XML index per submission sequence
Lifecycle Management	Manual tracking by sponsor and agency, with no systematic mechanism for current-view reconstruction	Automated sequence-based system enabling full current-view reconstruction at any point in the product's regulatory history
Regulatory Requirement	Historical format, no longer accepted by major regulatory authorities for new applications	Mandatory for NDAs, BLAs, ANDAs, and commercial INDs at FDA; all MAAs at EMA; and submissions to 60+ agencies globally

What are the 5 Modules in eCTD?

The five-module structure applies consistently across all eCTD submissions, regardless of application type or regulatory authority:

• Module 1 (Regional Information): Administrative and prescribing information specific to each market, including application forms, proposed labeling, cover letters, and region-specific requirements.

• Module 2 (CTD Summaries): Quality, nonclinical, and clinical overviews and summaries that synthesize the evidence in Modules 3, 4, and 5, including the Quality Overall Summary (QOS), clinical overview, and nonclinical overview, authored after the supporting modules are complete.

• Module 3 (Quality/CMC): Chemistry, Manufacturing, and Controls documentation covering drug substance characterization, drug product specifications, and manufacturing processes, all of which form the evidentiary base for the quality overviews in Module 2.

• Module 4 (Nonclinical Study Reports): Pharmacology, pharmacokinetics, and toxicology data from preclinical laboratory and animal studies.

• Module 5 (Clinical Study Reports): All human clinical trial data from Phase I through Phase III, including individual study reports with their Tables, Figures, and Listings, integrated summaries of safety and efficacy, and supporting clinical literature.

Which Application Types Use eCTD?

eCTD applies across the full spectrum of drug and biologic regulatory submissions to major health authorities:

• IND (Investigational New Drug): The application filed to obtain FDA authorization to begin clinical trials in humans. Commercial IND applications have been required in eCTD format since May 2018. Noncommercial INDs, including investigator-sponsored and expanded-access applications, are encouraged but not required to use eCTD.

• NDA (New Drug Application): Filed after Phase III to request commercial marketing approval for small-molecule drugs. BLA (Biologics License Application): The biologic equivalent of an NDA, covering vaccines, gene therapies, blood products, and other biological products. 

• ANDA (Abbreviated New Drug Application): Filed for generic drugs to demonstrate bioequivalence to an approved reference product.

• MAA (Marketing Authorization Application): The EMA pathway for marketing authorization across EU member states, submitted via the centralized, decentralized, or mutual recognition procedure. 

How AuroraPrime Produces eCTD-Ready Submission Content

An eCTD dossier's regulatory value depends on what goes inside the modules. The content across those five modules spans thousands of pages generated over years, often by multiple teams working in sequence and in parallel. It’s important to ensure consistency across that content.

AuroraPrime is an automation writing tool for drug development that addresses this at the authoring stage. It automates the generation of the documents that populate the eCTD's most complex modules, and keeps those documents consistent as content evolves across the development timeline:

• Module 5 Clinical Study Reports: AuroraPrime automates first-draft CSR generation from study source data, including Tables, Figures, and Listings synchronization, protocol automation, and lay summary generation.

• Module 2 Clinical Summaries and Overviews: AuroraPrime generates Module 2 clinical overviews and integrated clinical summaries directly from Module 5 source content, maintaining narrative consistency between study-level reports and the top-level summaries regulators review first.

• Cross-Module Quality Control: Built-in quality control for regulatory writing, benchmarked against validated reference documents, flags inconsistencies between modules before submission, targeting one of the most common sources of FDA review queries.

• Audit-Ready Traceability: Every authoring decision is tracked and documented across document versions, supporting eCTD lifecycle management and providing a complete, defensible record from source data through to final submission text.

As an AI writing solution for pharmaceutical companies, AuroraPrime integrates with Veeva RIM and Microsoft Word, allowing teams to maintain existing processes while improving cross-document consistency.

Book a demo to see how AuroraPrime produces submission-ready content across all five eCTD modules.